Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar M R, Diederichs C G, Von Baer A, Kotzerke J, Reske S N
Department of Trauma, Hand and Reconstructive Surgery, University of Ulm, Germany.
J Nucl Med. 2000 Oct;41(10):1695-701.
Clinical diagnosis of skeletal tumors can be difficult, because such lesions compose a large, heterogeneous group of entities with different biologic behaviors. The aim of this prospective study was to assess the value of PET in grading tumors and tumorlike lesions of bone.
Two hundred two patients with suspected primary bone tumors were investigated using FDG PET. Uptake of FDG was evaluated semiquantitatively by determining the tumor-to-background ratio (T/B). All patients underwent biopsy, resulting in the histologic detection of 70 high-grade sarcomas, 21 low-grade sarcomas, 40 benign tumors, 47 tumorlike lesions, 6 osseous lymphomas, 6 plasmacytomas, and 12 metastases of an unknown primary tumor.
All lesions, with the exception of 3 benign tumors, were detected by increased FDG uptake. Although sarcomas showed significantly higher T/Bs than did latent or active benign lesions (P < 0.001), aggressive benign lesions could not be distinguished from sarcomas. Using a T/B cutoff level for malignancy of 3.0, the sensitivity of FDG PET was 93.0%, the specificity was 66.7%, and the accuracy was 81.7%.
FDG PET provides a promising tool for estimating the biologic activity of skeletal lesions, implicating consequences for the choice of surgical strategy.
骨骼肿瘤的临床诊断可能具有挑战性,因为这类病变包含一大组生物学行为各异的异质性实体。本前瞻性研究的目的是评估正电子发射断层显像(PET)在骨肿瘤和肿瘤样病变分级中的价值。
对202例疑似原发性骨肿瘤患者进行了氟代脱氧葡萄糖(FDG)PET检查。通过测定肿瘤与本底比值(T/B)对FDG摄取进行半定量评估。所有患者均接受了活检,组织学检查发现70例高级别肉瘤、21例低级别肉瘤、40例良性肿瘤、47例肿瘤样病变、6例骨淋巴瘤、6例浆细胞瘤以及12例原发肿瘤不明的转移瘤。
除3例良性肿瘤外,所有病变均表现为FDG摄取增加。尽管肉瘤的T/B显著高于潜在或活动期良性病变(P < 0.001),但侵袭性良性病变与肉瘤难以区分。以T/B 3.0作为恶性肿瘤的临界值,FDG PET的敏感性为93.0%,特异性为66.7%,准确性为81.7%。
FDG PET为评估骨骼病变的生物学活性提供了一种有前景的工具,对手术策略的选择具有重要意义。